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ABSTRACT 
 
Background  
Venous thromboembolism (VTE) is a well recognised and preventable 
complication of acute stroke. While graduated compression stockings reduce the 
risk of VTE in surgical patients their benefit in acute stroke remains uncertain. 
 
Methods 
The relationship between symptomatic VTE and use of stockings using 
observational data from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’, which 
compared 10 days of treatment with tinzaparin (175 IU.kg-1 or 100 IU.kg-1) with,  
aspirin (300 mg od), was assessed using logistic regression adjusted for known 
VTE risk factors and treatment. 
 
Results 
Symptomatic VTE occurred in 28 patients (1.9%, DVT 18, PE 13) within 15 days 
of enrolment in 1,479 patients. Patients wearing one or two stockings for any 
period of time during the first 10 days (n=803) had a non-significant increase 
(odds ratio, OR 2.45, 95% confidence interval, CI 0.95 - 6.32) in the risk of 
symptomatic VTE. In contrast, those wearing bilateral stockings for 10 days 
(n=374) had a non-significant reduction in the odds of symptomatic VTE as 
compared to those who wore no stockings or wore them for less than 10 days 
(OR 0.65, 95% CI 0.26-1.65). Mild stroke and treatment with tinzaparin were 
associated with a reduced risk of VTE. 
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Conclusions 
Bilateral graduated compression stockings may reduce the incidence of VTE by 
one-third in patients with acute ischaemic stroke. However, the uncertainty in 
this finding, low frequency of symptomatic VTE, potential for stockings to cause 
harm, and cost of stockings highlight the need for a large randomised-controlled 
trial to examine the safety and efficacy of stockings in acute stroke. 
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INTRODUCTION 
 
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and/or 
pulmonary embolism (PE), were common clinical events in acute stroke 30 years 
ago.[1, 2] Symptomatic VTE (sVTE) rates have declined in the intervening time 
to a rate of 3-5%.[3-5] However, a recent study to detect sub-clinical DVT 
suggested that the rate of sub-clinical DVT remains high.[6] This is important as 
asymptomatic DVT is the commonest precursor of symptomatic PE,[7] a major 
cause of mortality in acute stroke,[8] and the usual precursor of fatal PE.[9] 
 
VTE can be prevented using drugs or compression stockings.[10] 
Unfractionated and low molecular weight heparins (LMWH) protect against DVT 
in surgical and medical patients [11, 12] and are used to treat diagnosed DVT 
and PE.[13] Aspirin also reduces the development of VTE [14] although probably 
less effectively so than anticoagulants. When considering patients with acute 
stroke, heparin offers effective prophylaxis against symptomatic DVT (sDVT) and 
symptomatic (sPE) but at the risk of causing intracranial haemorrhage.[3-5] 
Aspirin also reduces PE in acute stroke but at less risk of bleeding.[3] The 
individual effects of early mobilisation, rehydration and stockings are not well 
quantified. 
 
Compression stockings produce a pressure gradient from ankle to thigh, 
displacing blood from the superficial venous system and compressing the vein 
reducing its cross sectional area [15] thereby minimising venous stasis. 
Stockings reduced the risk of DVT by 57-64% in surgical patients,[16] and are 
also effective in medical patients.[17] There is no evidence as to whether full or 
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knee length stockings provide more benefit.[18] One randomised controlled trial 
(RCT) (n=98) was unable to demonstrate any significant benefit in acute stroke 
patients, although a trend towards DVT reduction was found (odds ratio 0.43, 
95% CI 0.14-1.36).[19] Stroke patients differ from post-operative surgical 
patients in important ways which might mean that stockings are less effective 
after stroke. In surgical prophylaxis, immobilisation is preceded by application of 
stockings and lasts only a few days. In contrast, paralysis occurs prior to 
stocking application in patients with stroke and may last weeks or months. The 
use of stockings may cause complications in patients with peripheral vascular 
disease and diabetes.[20, 21] 
 
Despite the theoretical effectiveness and widespread use of stockings, 
their clinical effectiveness needs further appraisal in stroke patients. We describe 
here the relationship between the use of stockings and effect on VTE using data 
from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST).  
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METHODS 
 
Design 
We performed a nested-observational study assessing the relationship between 
the use of graduated venous compression stockings and subsequent venous 
thromboembolic events. Data were obtained from the TAIST randomised 
controlled trial [4] and adjusted for confounding factors. 
 
TAIST 
TAIST was a prospective, randomised, multicentre, double-blind, aspirin-
controlled trial assessing the safety and efficacy of tinzaparin, a low molecular 
weight heparin, in 1,484 patients with acute ischaemic stroke.[4] Patients were 
enrolled within 48 hours of ictus and randomly assigned to 10 days of treatment 
with high-dose tinzaparin (175 IU.kg-1), medium-dose tinzaparin (100 IU.kg-1), 
or aspirin (300 mg). The stroke centres taking part in TAIST were all expert in 
stroke care and experienced in trials. 
 
Stockings and venous thromboembolic events 
The decision to prescribe stockings and how these would be used was left to the 
responsible physician and local practice and is likely, therefore, to have been 
dependent on certain clinical features such as stroke severity, immobility and 
contraindications to stockings. Similarly, the decision to refer patients for 
physical therapy and early mobilisation, factors which can also reduce VTE, was 
left to local practice. The use of stockings and whether these were bilateral or 
unilateral was prospectively recorded on a daily basis during the 10 days of drug 
treatment. 
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During the treatment period patients were examined for signs and 
symptoms of sVTE on a daily basis with venography or venous duplex scanning 
being used to confirm the diagnosis of sDVT, and ventilation perfusion scan to 
confirm the diagnosis of PE. The incidence of sDVT and/or sPE was documented 
again at 90 and 180 days of follow-up after a review of medical records and 
patient interview. An independent committee blinded to treatment assignment 
(and the wearing of stockings) adjudicated the diagnosis of major events, 
including DVT, PE and death. 
 
Data management 
Patients were categorised into those who wore stockings (on either leg at any 
point during the treatment period or those who wore bilateral stockings for the 
whole treatment period) and those who did not. The primary analysis focused on 
VTE events occurring within 15 days of enrollment, equivalent to the ten days of 
randomised treatment plus 5 days to allow for the antithrombotic effects of the 
trial interventions to dissipate.[4] Comparisons of VTE were also made at 90 and 
180 days. 
 
Statistical analysis  
Intention-to-treat analyses were performed using SAS version 8 (SAS Institute, 
Cary NC). Data are given as frequency (%), median (interquartile range), and 
odds ratio (OR) with 95% confidence intervals (95% CI). Differences between 
groups were assessed with either a chi square test or the Wilcoxon test. 
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Differences in the incidence of VTE were investigated using logistic 
regression adjusted for the use of stockings, treatment (high dose tinzaparin, 
medium dose tinzaparin, aspirin) and known VTE risk factors, including age, 
gender, smoking status (current smoker vs. past or non smoker), weight, stroke 
severity (assessed using the Scandinavian Stroke Scale, SSS) and time to 
enrollment. Logistic regression models were created comprising accepted VTE 
risk factors even if these were not significant univariate factors in this study. Two 
models were produced: a comparison of patients who wore: (i) one or two 
stockings at any point during the 10 days versus those who wore none; and (ii) 
bilateral stockings for the whole ten days versus those who wore no stockings or 
wore them for less than 10 days. 
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RESULTS 
 
Subjects 
Of the 1,499 patients randomised, 15 were excluded from the trial’s primary 
analysis due to emerging exclusion criteria (such as the discovery of contra-
indications to treatment), leaving 1,484 patients (aspirin 491, medium dose 
tinzaparin 507, high dose tinzaparin 486).[4] A further 5 patients were excluded 
from the present analyses because no information on stockings was recorded at 
any time point. 
 
Stockings 
The baseline characteristics of the 1,479 (99.7%) included patients are shown in 
table 1. Just over half (803, 54%) wore stockings at some point during the first 
10 days post enrollment. Patients given stockings had more severe stroke, 
judged by their lower baseline SSS score and the greater proportion of patients 
with a total anterior circulation syndrome (TACS).[22] The frequency of other 
characteristics, including demographic and vascular risk factors (including prior 
stroke, myocardial infarction, smoking, atrial fibrillation, diabetes and 
intermittent claudication), were similar between stocking and non-stocking users 
(table 1). 
 
Venous thromboembolism 
Patients with a severe stroke (lower SSS score, TACS clinical syndrome), leg 
weakness, or right-sided weakness were more likely to suffer a VTE (table 2). 
Other risk factors were similar (data not shown). VTE occurred more frequently 
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in those wearing stockings or taking aspirin (as compared to those receiving 
medium or high dose tinzaparin). 
 
The overall incidence of sVTE by 15 days post-enrollment was low at 1.9% 
(table 3). Patients given stockings had a significantly higher incidence of sVTE at 
15 days as compared to non stocking wearers (0.9% versus 2.7%, p=0.01, table 
3). Similar increases in the components of sVTE, sDVT and sPE were seen in 
those with stockings. The difference in sVTE was maintained during the 
subsequent 180 days (table 3). The median time to sVTE was 10 days (IQR 5.5-
13) and did not differ between those with and without stockings. 
 
Case-fatality by 15 days post-enrollment was comparable between 
stocking and non-stocking wearers (table 3). Of the 216 deaths by day 180, PE 
was adjudicated to be the cause of death in 11 cases (5.1%) and was clinically 
evident in 10 of these (3 patients had an autopsy confirming PE as cause of 
death). The remaining patient had unexplained sudden death with PE diagnosed 
at autopsy. A total of 22 autopsies were performed out of 216 deaths (10.2%); 
only 4 patients showed evidence of PE at postmortem. 
 
Stockings and symptomatic venous thromboembolism 
Patients wearing one or two stockings for any period of time during the first 10 
days (n=803) had a non-significant 2.45 (95% CI, 0.95 - 6.32) fold increase in 
the risk of sVTE during the first 15 days, with adjustment for age, gender, 
impairment, weight, smoking, time to enrollment, and treatment (figure 1). 
Tinzaparin reduced sVTE in a dose-dependent fashion as compared with aspirin. 
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Symptomatic VTE events were few in number (6, 1.6%) when considering 
the 374 patients who wore bilateral stockings for the whole of the first ten days 
after enrollment. Patients wearing bilateral stockings for 10 days had a non-
significant 35% reduction in the odds of symptomatic VTE as compared to those 
who wore no stockings or wore them for less than 10 days, OR 0.65 (95% CI, 
0.26 - 1.65, figure 2). 
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DISCUSSION 
 
This study is the largest in stroke to assess, in a systematic manner, whether 
graduated compression stockings reduce symptomatic VTE events. The incidence 
of sVTE was low at 2 weeks and 6 months post stroke (1.9% and 4.9% 
respectively) confirming recent findings [3, 5] that it is becoming less common, 
presumably secondary to improved care including early mobilisation, early 
rehydration and increased use of aspirin. 
 
In univariate analyses, the wearing of stockings was associated with a 
significant increased risk of sVTE. Since it is likely that this reflected confounding 
by known risk factors, especially stroke severity, two logistic regression models 
were used to adjust for potential confounders. The first model compared patients 
who wore any stockings at any time during the first 10 days with those who wore 
no stockings whatsoever; the wearing of stockings was still associated with an 
increase in sVTE, albeit non-significant. In the second model, rigorous wearing of 
stockings bilaterally for the first 10 days was associated with a reduction in sVTE 
of about 35% as compared with patients who wore no stockings or who only 
wore them for part of the 10 days. The lack of statistical significance could 
simply reflect chance, in which case stockings are apparently ineffective in 
preventing sVTE in patients with acute stroke. However, a number of other 
factors are relevant potentially. First, very few sVTE events were recorded 
thereby limiting the power of these analyses. Second, the point estimate in the 
second model appears to be less than that seen in surgical prophylaxis where the 
reduction approximates to 57-64%,[16] perhaps reflecting that prevention 
should, ideally, commence before the period of risk starts. Third, comparison of 
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the two models suggests that the use of stockings should be systematic and 
rigorous, i.e. they should be placed bilaterally and used to cover the whole period 
of immobility rather than be used ad hoc. Forth, other powerful modulators of 
VTE may have concealed part of the effect of stockings, especially the use of a 
LMWH. This is very relevant in a non-randomised observational study where the 
factor being assessed has a moderate treatment effect. Last, the multivariate 
models may not have included important confounding factors. 
 
A number of caveats need to be made about the findings reported here. 
First, this was a longitudinal substudy of a randomised-controlled trial. 
Observational studies are susceptible to bias, as was apparent here with the 
increased use of stockings in more severe patients. Such bias can mask or inflate 
findings. The univariate analysis and one of the models suggested that stockings 
might increase VTE. Full-length stockings can slip or roll down [23] and lead to a 
tourniquet effect around the knee thereby, potentially, reducing venous return 
[24] and increasing the risk of DVT. Additionally, patients with sensory loss (e.g. 
due to diabetes), perceptual changes (e.g. neglect) or dysphasia may not be able 
to signal distress from inappropriately applied or maintained stockings. Hence, 
the possible ineffectiveness or even hazard with stockings needs to be refuted in 
a randomised controlled trial. (Interestingly, the frequency of diabetes mellitus 
and intermittent claudication, conditions which are relative contraindications for 
the use of stockings, did not differ between the two groups.) Second, the 
subjects in TAIST were selected because of inclusion/exclusion criteria relating to 
a trial of a low molecular weight heparin. Hence, the results here may not be 
generalisable to all patients with ischaemic stroke, and have questionable 
relevance to patients with primary intracerebral haemorrhage. Third, the use of 
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stockings was only recorded for the first 10 days after enrollment thereby 
potentially reducing the apparent effect of stockings. 
 
Forth, this study recorded only sVTE and it is possible that a substantial 
number of asymptomatic VTE cases were missed. As mentioned previously this is 
important as asymptomatic DVT is the usual precursor of fatal PE.[9] Using DVT 
as a surrogate marker for PE, it is possible to hypothesize that reducing DVT will 
reduce PE; however these reductions in PE are inferred, rather than based on 
trial data. To date, the largest thromboprophylactic trial in medical patients 
showed that there was no beneficial effect of heparin on the incidence of fatal PE 
and total mortality.[25] Furthermore, the signs and symptoms of VTE may be 
misinterpreted, e.g. PE may be diagnosed as pneumonia.[26] Fifth, despite the 
diagnosis of VTE being independently adjudicated, varying diagnostic techniques 
were used at different centers (e.g. DVT was confirmed using either venography 
and duplex ultrasound) thereby introducing the potential for variation in the 
incidence of DVT across centers. Sixth, the information recorded on the use of 
stockings was limited and did not include data on the type of stocking (full length 
versus below knee, manufacturer), or adverse events and discontinuations 
related to the wearing of stockings. Last, DVT might be diagnosed less in 
patients wearing stockings since these mask signs such as swelling, temperature 
and colour change (unless they are removed regularly to expose the legs) whilst 
stroke patients often have communication difficulties, e.g. confusion and 
dysphasia, thereby limiting their ability to mention the presence of symptoms. 
 
Despite these limitations, the results come from a large study with high 
fidelity data collection and blinded adjudication of sVTE events. Overall, stockings 
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might reduce the rate of sVTE by around one-third in patients with acute 
ischaemic stroke. However, the uncertainty in this finding, low frequency of 
symptomatic VTE, potential for stockings to cause harm (e.g. gangrene in 
patients with peripheral artery disease), and cost of stockings (financial, nursing 
time, patient discomfort) all raise questions as to their place in acute stroke 
management. These issues highlight the need for one or more large randomised 
controlled trials to test the safety, efficacy and health economics of stockings in 
this patient group. The ongoing ‘Clots in Legs Or TEDs after Stroke’ (CLOTS, 
www.clotstrial.com) trial is examining whether stockings reduce both 
symptomatic and asymptomatic DVT, and whether long stockings are more 
effective than short ones, in over 5,000 patients.[27] 
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TABLE 1 
Baseline characteristics of patients wearing or not wearing stockings. Number 
(%) or median (interquartile range); comparison by Chi square test or Wilcoxon 
test. 
 Total No 
stockings 
Stockings † p value 
Subjects  1,479 676 (46) 803 (54)  
Age (years) 74 (66-80) 75 (67-80) 73 (64-79) 0.004 
Gender, male (%) 804 (55.4) 377 (55.8) 427 (53.2) 0.32 
Weight (kg) 72 (63-82) 72 (63-82) 72.7 (63-
82) 
0.39 
Clinical:     
  Time to enrollment (hour) 25 (15.3-
37.0) 
25 (16-38) 25 (14-37) 0.34 
  Side of lesion, right (%) 769 (53.2) 350 (53.4) 419 (53.1) 0.92 
  Impairment (SSS), total 34 (24-42) 38 (28-46) 30 (20-39) <0.0001 
  Impairment (SSS), leg 4 (2-5) 4 (2-5) 4 (0-5) <0.0001 
  Impairment (SSS), gait 3 (0-6) 3 (0-6) 0 (0-3) <0.0001 
Oxford classification:     
  TACI (%) 519 (35.1) 193 (28.6) 236 (40.6) <0.0001 
  PACI (%) 471 (31.9) 216 (32) 255 (31.8) 0.94 
  LACI (%) 422 (28.5) 243 (36) 179 (22.3) <0.0001 
  POCI (%) 66 (4.5) 23 (3.4) 43 (5.4) 0.07 
Antithrombotic 
(randomised) 
    
  Tinzaparin, high dose (%) 484 (32.7) 223 (33.0) 261 (32.5) 0.84 
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  Tinzaparin, medium dose 
(%) 
505 (34.1) 229 (33.9) 276 (34.4) 0.84 
  Aspirin (%) 490 (33.1) 224 (33.1) 226 (33.1) 0.99 
† Worn for any number of days within the 10 treatment period on either or both 
legs 
 LACI: lacunar infarct; PACI: partial anterior circulation infarct; POCI: posterior 
circulation syndrome; SSS: Scandinavian Stroke Scale (total, leg and gait scores; 
low score ~ severe stroke); TACI: total anterior circulation infarct 
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TABLE 2 
Baseline characteristics of patients developing or not developing sVTE. Number 
(%) or median (interquartile range); comparison by Chi square test or Wilcoxon 
test. 
 No sVTE sVTE p value 
Subjects 1451 (98.1%) 28 (1.9%)  
Clinical details    
  Age (years)  74 (66-80) 71 (69.5-79) 0.99 
  Gender, male (%) 792 (54.6) 12 (42.9) 0.22 
  Severity (SSS) 34 (24-43) 22.5 (10-
34.5) 
0.0001 
  Leg impairment (SSS) 4 (2-5) 2 (0-4) 0.004 
  Gait impairment (SSS) 3 (0-6) 0 (0-3) 0.05 
  Oxford classification, TACI (%) 504 (34.7) 15 (53.6) 0.04 
  Weakness, right (%) 746 (52.7) 23 (82.1) 0.002 
Management    
  Time to enrollment (hours) 25 (15.4-
37.0) 
25.7 (9.9-
42.2) 
0.80 
  Compression stockings, any (%) 781 (53.8) 22 (78.6) 0.01 
  Compression stockings, for 10 days 
(%) 
368 (25.4) 6 (21.4) 0.64 
  No stockings (%) 670 (46.2) 6 (21.4) 0.01 
  Tinzaparin, high dose (%) 479 (33.0) 5 (17.9) 0.09 
  Tinzaparin, medium dose (%) 498 (34.3) 7 (25.0) 0.30 
  Aspirin (%) 474 (32.7) 16 (57.1) 0.01 
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SSS: Scandinavian Neurological Stroke Scale (low score ~ severe stroke); TACI: 
total anterior circulation infarct 
 
21 
TABLE 3 
Venous thromboembolic events and case-fatality by the wearing of stockings. 
Number (%); comparison by Chi square test. 
 No stockings Stockings p value 
Subjects 676 803  
Day 15:*    
  Deep vein thrombosis (%) 5 (0.7) 13 (1.6) 0.12 
  Pulmonary embolism (%) 2 (0.3) 11 (1.4) 0.03 
  Venous thromboembolic events (%) 6 (0.9) 22 (2.7) 0.01 
  Dead (%) 27 (4.0) 58 (7.2) 0.01 
Day 90:†    
  Deep vein thrombosis (%) 13 (1.9) 39 (4.9) 0.002 
  Pulmonary embolism (%) 2 (0.3) 19 (2.4) 0.001 
  Venous thromboembolic events (%) 14 (2.1) 55 (6.8) <0.0001 
  Dead (%) 62 (9.2) 116 (14.4) 0.002 
Day 180:†    
  Deep vein thrombosis (%) 13 (1.9) 41 (5.1) 0.001 
  Pulmonary embolism (%) 2 (0.3) 20 (2.5) 0.001 
  Venous thromboembolic events (%) 14 (2.1) 58 (7.2) <0.0001 
  Dead (%) 76 (11.2) 140 (17.4) 0.001 
* End of treatment plus 5 days 
† Cumulative total 
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FIGURE LEGENDS 
 
FIGURE 1 
Odds ratios and 95% confidence intervals for the occurrence of VTE for all 
stocking wearers. 
 
FIGURE 2 
Odds ratios and 95% confidence intervals for the occurrence of VTE for those 
wearing stocking bilaterally for 10 days 
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FIGURE 1 
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FIGURE 2 
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